IL-22 a member of a group of cytokines called the IL-10 family or IL-10 superfamily (including IL-19, IL-20, IL-24, and IL-26), a class of potent mediators of cellular inflammatory responses. It shares use of IL-10R2 in cell signaling with other members of this family, IL-10, IL-26, IL-28A/B and IL-29. IL-22 is produced by activated DC and T cells and initiates innate immune responses against bacterial pathogens especially in epithelial cells such as respiratory and gut epithelial cells. IL-22 along with IL-17 is rapidly produced by splenic LTi-like cells  and can be also produced by Th17 cells and likely plays a role in the coordinated response of both adaptive and innate immune systems.
IL-22 biological activity is initiated by binding to a cell-surface complex composed of IL-22R1 and IL-10R2 receptor chains and further regulated by interactions with a soluble binding protein, IL-22BP, which shares sequence similarity with an extracellular region of IL-22R1 (sIL-22R1). IL-22 and IL-10 receptor chains play a role in cellular targeting and signal transduction to selectively initiate and regulate immune responses. IL-22 can contribute to immune disease through the stimulation of inflammatory responses, S100s and defensins. IL-22 also promotes hepatocyte survival in the liver and epithelial cells in the lung and gut similar to IL-10. In some contexts, the pro-inflammatory versus tissue-protective functions of IL-22 are regulated by the often co-expressed cytokine IL-17A 
IL-22, signals through the interferon receptor-related proteins CRF2-4 and IL-22R. It forms cell surface complexes with IL-22R1 and IL-10R2 chains resulting in signal transduction through receptor, IL-10R2. The IL-22/IL-22R1/IL-10R2 complex activates intracellular kinases (JAK1, Tyk2, and MAP kinases) and transcription factors, especially STAT3. It can induce IL-20 and IL-24 signaling when IL-22R1 pairs with IL-20R2.
Crystallization is possible if the N-linked glycosylation sites are removed in mutants of IL-22 bound with high-affinity cell-surface receptor sIL-22R1. The crystallographic asymmetric unit contained two IL-22-sIL-22R1 complexes.
^ abXie MH, Aggarwal S, Ho WH, Foster J, Zhang Z, Stinson J, Wood WI, Goddard AD, Gurney AL (October 2000). "Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R". J. Biol. Chem.275 (40): 31335–9. doi:10.1074/jbc.M005304200. PMID10875937.
^Witte K, Witte E, Sabat R, Wolk K (Aug 2010). "IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties". Cytokine Growth Factor Rev21 (4): 237–51. doi:10.1016/j.cytogfr.2010.04.002. PMID20655797.
Liu Y, Yang B, Zhou M, et al. (2009). "Memory IL-22-producing CD4+ T cells specific for Candida albicans are present in humans". Eur. J. Immunol.39 (6): 1472–9. doi:10.1002/eji.200838811. PMID19449309.
He M, Liang P (2010). "IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis". J. Immunol.184 (4): 1793–8. doi:10.4049/jimmunol.0901829. PMID20061404.
Wolk K, Witte E, Warszawska K, et al. (2009). "The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis". Eur. J. Immunol.39 (12): 3570–81. doi:10.1002/eji.200939687. PMID19830738.
Dhiman R, Indramohan M, Barnes PF, et al. (2009). "IL-22 produced by human NK cells inhibits growth of Mycobacterium tuberculosis by enhancing phagolysosomal fusion". J. Immunol.183 (10): 6639–45. doi:10.4049/jimmunol.0902587. PMID19864591.
Cella M, Fuchs A, Vermi W, et al. (2009). "A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity". Nature457 (7230): 722–5. doi:10.1038/nature07537. PMID18978771.